Pfizer accused of Covid profiteering as first-quarter sales hit $26bn - The Guardian

Pharma firm criticised over pricing and for keeping monopoly control over vaccine and new Paxlovid pill

Pfizer has made nearly $26bn (£21bn) in revenues in the first three months of the year, the bulk from its Covid-19 vaccine and new pill to treat the virus, prompting fresh accusations of pandemic pro… [+3193 chars]

full article...